Literature DB >> 32661849

Breast-Conserving Therapy is Associated with Improved Survival Compared with Mastectomy for Early-Stage Breast Cancer: A Propensity Score Matched Comparison Using the National Cancer Database.

Erica Wrubel1,2, Raylene Natwick3,4, G Paul Wright3,4,5.   

Abstract

INTRODUCTION: Current recommendations for early-stage breast cancer are largely based on the NSABP B-06 trial demonstrating equivalent survival between mastectomy and lumpectomy. We sought to compare breast-conserving therapy (BCT) with mastectomy for treatment of early-stage breast cancer in a contemporary patient population.
METHODS: A query of the NCDB PUF identified female breast cancer patients diagnosed from 2004 to 2015. Patients with stage I or II disease were included. BCT was defined as the receipt of lumpectomy plus radiation. Propensity scores were tabulated using race, age, Charlson/Deyo score, tumor site, laterality, histology, grade, size, number of nodes positive, lymph-vascular invasion, receptor status, receipt of chemotherapy, and endocrine therapy. Patients who received BCT versus mastectomy were matched using a 1:1 nearest neighbor technique. The primary outcome measured was overall survival.
RESULTS: After exclusions and matching, two equal groups of 101,118 patients remained. Median follow-up was 42 months. The majority had invasive ductal histology (77%), and node-negative disease (84%). Receptor status included ER-positive (83%), PR-positive (73%), and HER2/Neu-positive (15%). Chemotherapy was received in 38% and endocrine therapy in 71%. Propensity score matching yielded equivalent groups across all target variables. The 5-year overall survival was superior for BCT compared with mastectomy (92.9% vs. 89.7%, p < 0.001; Fig. 1). This survival advantage persisted for both stage I (p < 0.001) and stage II (p < 0.001) disease on subgroup analysis. Fig. 1 Overall survival in female patients with early stage invasive breast cancer (stage I or II) undergoing breast conservation surgery with radiation compared with mastectomy. BCS breast conservation surgery
CONCLUSIONS: BCT is associated with superior overall survival compared with mastectomy for early-stage breast cancer using well-matched, contemporary data.

Entities:  

Mesh:

Year:  2020        PMID: 32661849     DOI: 10.1245/s10434-020-08829-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  1 in total

1.  Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis.

Authors:  T J Whelan; J Julian; J Wright; A R Jadad; M L Levine
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

  1 in total
  9 in total

1.  A propensity score-matched analysis of breast-conserving surgery plus whole-breast irradiation versus mastectomy in breast cancer.

Authors:  Francesca Magnoni; Giovanni Corso; Patrick Maisonneuve; Giulia Massari; Luca Alberti; Giulia Castelnovo; Maria Cristina Leonardi; Virgilio Sacchini; Viviana Galimberti; Paolo Veronesi
Journal:  J Cancer Res Clin Oncol       Date:  2022-03-07       Impact factor: 4.553

2.  Recurrence Yield of Stereotactic Biopsy of Suspicious Calcifications After Breast Conservation Therapy.

Authors:  Javaria Aleem; Sara Rehman; Mehreen Shafqat; Hamd Zahra; Javeria Ashraf; Imran Khalid Niazi
Journal:  Cureus       Date:  2022-04-20

3.  Oncoplastic surgery: A suitable alternative to conventional breast conserving surgery in low - Middle income countries; a retrospective cohort study.

Authors:  Syeda Sakina Abidi; Lubna Mushtaque Vohra; Muhammad Rizwan Javed; Nargis Khan
Journal:  Ann Med Surg (Lond)       Date:  2021-07-29

4.  Patient-level costs of staged unilateral versus immediate bilateral symmetrization mammoplasty in breast-conserving surgery.

Authors:  Yasmin Grant; Paul T R Thiruchelvam; Lana Kovacevic; Elias Mossialos; Ragheed Al-Mufti; Katy Hogben; Dimitri J Hadjiminas; Daniel R Leff
Journal:  BJS Open       Date:  2022-05-02

5.  Research on Effectiveness of Prior Cancer on Survival Outcomes for Patients with Nonmetastatic Triple-Negative Breast Cancer: A Competing Risk Analysis and Propensity Score Matching Analysis of the SEER Database.

Authors:  Heyan Chen; Lutong Yan; Shengyu Pu; Lizhe Zhu; Huimin Zhang; Can Zhou
Journal:  J Oncol       Date:  2021-09-17       Impact factor: 4.375

6.  Spatiotemporal Patterns of Loco-Regional Recurrence After Breast-Conserving Surgery.

Authors:  Fei-Lin Qu; Rui Mao; Zhe-Bin Liu; Cai-Jin Lin; A-Yong Cao; Jiong Wu; Guang-Yu Liu; Ke-Da Yu; Gen-Hong Di; Jun-Jie Li; Zhi-Ming Shao
Journal:  Front Oncol       Date:  2021-08-30       Impact factor: 6.244

7.  Prognostic Factors and a Nomogram Predicting Survival in Patients with Breast Ductal Carcinoma in situ with Microinvasion: A Population-Based Study.

Authors:  Yi-Zi Zheng; Hong-Bin Qin; Zi-Zheng Li; He-Sheng Jiang; Greg Zhang; Shi-Wei Yang; Xian-Ming Wang; Yang-Chun Xu; Zhen-Han Deng; Guo-Wen Liu
Journal:  Clin Epidemiol       Date:  2021-11-30       Impact factor: 4.790

8.  Breast-conserving therapy is associated with better survival than mastectomy in Early-stage breast cancer: A propensity score analysis.

Authors:  Jiali Ji; Shushu Yuan; Jiawei He; Hong Liu; Lei Yang; Xuexin He
Journal:  Cancer Med       Date:  2022-02-25       Impact factor: 4.452

9.  Survival Outcomes of Breast-Conserving Therapy versus Mastectomy in Early-Stage Breast Cancer, Including Centrally Located Breast Cancer: A SEER-Based Study.

Authors:  Tianshui Yu; Weilun Cheng; Ting Wang; Ziang Chen; Yu Ding; Jianyuan Feng; Yunqiang Duan; Anbang Hu; Mingcui Li; Hanyu Zhang; Yanling Li; Fei Ma; Baoliang Guo
Journal:  Breast J       Date:  2022-08-27       Impact factor: 2.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.